Treatment of early non-response in patients with schizophrenia: Assessing the efficacy of antipsychotic dose escalation

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Loebel, Antony ^a   Citrome, Leslie ^b,d   Correll, Christoph U ^c   Xu, Jane ^a   Cucchiaro, Josephine ^a   Kane, John M ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

Antipsychotic; Dosing; Early responder; Lurasidone; Schizophrenia; Study design

Indexed keywords

LURASIDONE; NEUROLEPTIC AGENT; PLACEBO; ISOINDOLE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; INTERNATIONAL COOPERATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOINDOLES; LURASIDONE HYDROCHLORIDE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945901098     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-015-0629-0     Document Type: Article

References (22)

1. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230-40.
2. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228-35.
3. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543-9.
4. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2013;160:2063-5.
5. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581-90.
6. Correll CU, Pikalov A, Hsu J, Cucchiaro J, Goldman R, Loebel A. Early improvement predicts endpoint response to lurasidone in schizophrenia: pooled analysis of five double-blind trials. Poster presentation. American Psychiatric Association, May 3-7, 2014, New York, NY
7. Hatta K, Ito H. Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia. Clin Psychopharmacol Neurosci. 2014;12:1-7.
8. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993;29:309-14.
9. Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2011;31:160-8.
10. Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:13-20.
11. GoffDC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013;33:485-90.
12. Latuda: US Package Insert. 2013. [http://www.latuda.com/LatudaPrescribingInformation.pdf]. Accessed October 12, 2015.
13. Latuda: EU Summary of Product Characteristics. 2014. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002713/WC500164683.pdf]. Accessed October 12, 2015.
14. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial. Schizophr Res. 2013;145:101-9.
15. Chapel S, Chiu YY, Hsu J, Xu J, Cucchiaro, Loebel A. Dose-response model of lurasidone treatment in schizophrenia. Poster presentation. American Psychiatric Association, May 5-9, 2012, Philadelphia, PA
16. US Food and Drug Administration: NDA Approval letter. [http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/200603s000ltr.pdf]. Accessed October 12, 2015.
17. Vermeiden M, Kamperman AM, Vulink ME, van den Broek WW, Birkenhäger TK. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl). 2015;232:1347-56.
18. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-53.
19. Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011;72:1236-41.
20. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13:155-72.
21. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392-400.
22. Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, et al. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur Psychiatry. 2009;24:501-6.